Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis

Abstract

Key Clinical Message Malignancies were reported in some studies following taking Fingolimod. We reported a case of bladder lymphoma after taking Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it with safer medicines. Abstract Fingolimod is a medication with a potential cure to control multiple sclerosis (MS) relapses. Here we describe a 32‐year‐old woman with relapsing–remitting multiple sclerosis who developed bladder lymphoma induced by long‐term use of Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it with safer medicines.

A Case of Primary Central Nervous System Lymphoma That Developed in a Patient Receiving Fingolimod Therapy for Multiple Sclerosis

“…In reports on the adverse events of fingolimod, malignant lymphoma was reported in various organs, such as the bladder, eye, mediastinum, and skin [10][11][12][13]. Many of these cases were associated with EB virus infection and were worsened by fingolimod treatment.…”